

1 **Role of Drugs used for chronic disease management on Susceptibility and**
2 **Severity of COVID-19: A Large Case-Control Study**

3 Huadong Yan^{1,2*}, Ana M Valdes^{3,4*}, Amrita Vijay^{4,5#}, Shanbo Wang⁶, Lili Liang¹,
4 Shiqing Yang¹, Hongxia Wang^{1,7}, Xiaoyan Tan⁶, Jingyuan Du¹, Susu Jin¹, Kecheng
5 Huang⁶, Fanrong Jiang⁸, Shun Zhang², Nanhong Zheng¹, Yaoren Hu¹, Ting Cai^{1,2#},
6 Guruprasad P. Aithal^{4,5,#}.

7

8 1) Department of Infectious Diseases, Hwamei Hospital, Ningbo No.2 Hospital,
9 University of Chinese Academy of Sciences., Ningbo 315010, China

10 2) Department of New Medical Science, Key Laboratory of Diagnosis and
11 Treatment of Digestive System Tumors of Zhejiang Province, Hwamei Hospital,
12 Ningbo No.2 Hospital, University of Chinese Academy of Sciences, Ningbo
13 315010, China

14 3) NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals
15 NHS Trust and University of Nottingham, Nottingham, UK.

16 4) Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine,
17 University of Nottingham, Nottingham

18 5) Nottingham Digestive Diseases Centre, School of Medicine, University of
19 Nottingham, Nottingham UK.

20 6) Department of General Practice, Gulin Township Health Center, Ningbo 315010,
21 China

22 7) Department of Infectious Diseases, Ninghai No.1 Hospital, Ningbo 315600, China

23 8) Department of Pharmacology, Hwamei Hospital, Ningbo No.2 Hospital, University
24 of Chinese Academy of Sciences., Ningbo 315010, China

25 *Joint first authors

1 # Joint Corresponding authors: Guruprasad P. Aithal, Nottingham Digestive
2 Diseases Centre, School of Medicine, University of Nottingham, Nottingham UK.
3 Email address: Guru.Aithal@nottingham.ac.uk. Amrita Vijay, Nottingham
4 Digestive Diseases Centre, School of Medicine, University of Nottingham,
5 Nottingham UK. Email address: Amrita.vijay@nottingham.ac.uk.
6 Ting Cai, Department of Infectious Diseases, Key Laboratory of Diagnosis and
7 Treatment of Digestive System Tumors of Zhejiang Province, Hwamei Hospital,
8 Ningbo No.2 Hospital, University of Chinese Academy of Sciences, Ningbo
9 315010, China. Email address: caiting@ucas.ac.cn.

10

11 **Funding:** By the Social Development Major Projects of Ningbo City (2016C51005),
12 Medical Health Science and Technology Project of Zhejiang Provincial Health
13 Commission (2018ZD039), Zhejiang Provincial natural science foundation
14 (LGF20H030006) and by the NIHR Nottingham Biomedical Research Centre
15 (Reference no: BRC-1215-20003).

16

17 **Conflict of interest**

18

19 GPA is an advisory board member for Amryt Pharmaceuticals, Astra Zeneca, GSK,
20 and Pfizer. AMV is a consultant for Zoe Global Ltd and member of the scientific
21 advisory board of CPKelco. All other authors declared no competing interests for this
22 work.

23

24

25

26

1 **Abstract**

2 The study aimed to investigate whether specific medications used in the treatment
3 chronic diseases affected either the development and/ or severity of COVID-19 in a
4 cohort of 610 COVID-19 cases and 48,667 population-based controls from Zhejiang,
5 China. Using a cohort of 578 COVID-19 cases and 48,667 population-based controls
6 from Zhejiang, China we tested the role of usage of cardiovascular, antidiabetic and
7 other medications on risk and severity of COVID 19. Analyses were adjusted for age,
8 sex and BMI and for presence of relevant comorbidities. Individuals with
9 hypertension taking calcium channel blockers had significantly increased risk [odds
10 ratio (OR)= 1.73 (95% CI 1.2-2.3)] of manifesting symptoms of COVID-19 whereas
11 those taking angiotensin receptor blockers and diuretics had significantly lower
12 disease risk (OR=0.22; 95%CI 0.15-0.30 and OR=0.30; 95%CI 0.19-0.58
13 respectively). Among those with type 2 diabetes, dipeptidyl peptidase-4 inhibitors
14 (OR= 6.02; 95% CI 2.3-15.5) and insulin (OR= 2.71; 95% CI 1.6-5.5) were more and
15 glucosidase inhibitors were less prevalent (OR= 0.11; 95% CI 0.1-0.3) among with
16 COVID-19 patients.

17 Drugs used in the treatment of hypertension and diabetes influence the risk of
18 development of COVID-19, but, not its severity.

19 **Keywords:** COVID-19; Antihypertensive medications; Antidiabetic medications;
20 Corticosteroids; Calcium channel blockers; Severity; Risk

21

22

23

24

1

2 **Study highlights**

3 What is the current knowledge on the topic?

4

5 Cardiovascular disease and Diabetes have been highlighted as comorbidities
6 contributing to a more severe form of COVID-19 and medication to treat them may
7 also influence the risk of COVID-19 and its clinical outcomes.

8

9 What question did this study address?

10

11 Does specific medications used in the treatment of chronic diseases influence the
12 risk for the susceptibility to SARS CoV-2 infection or severity of COVID-19?

13

14 What does this study add to our knowledge?

15

16 The study confirms that higher BMI, diabetes and cardio/ cerebrovascular disease as
17 independent risk factors for the development of COVID-19. Angiotensin Receptor
18 Blockers (ARBs) and diuretics were associated with reduced risk and Calcium
19 Channel Blockers (CCBs) with increased risk of developing COVID-19. Among those
20 with type 2 diabetes, dipeptidyl peptidase-4 and were associated with increased and
21 glucosidase inhibitors with reduced risk development of COVID-19. None of the
22 antihypertensive or anti-diabetic drugs were associated with increased risk of severe
23 or critical form of the infection.

24 Drugs used in the treatment of hypertension and diabetes influence the risk of
25 development of COVID-19, but are not associated with severity of the disease.

26

27 How might this change clinical pharmacology or translational science?

28

29 Findings from the current large case-control study confirmed no evidence to alter
30 ARBs or ACEIs therapy in the context of COVID-19 severity in clinical practice.

31 Hypertension significantly increases the risk of severe or critical SARS-CoV-2
32 infection indicating that carefully controlled blood pressure should be a priority to
33 reduce the healthcare burden of COVID-19.

34

35

1

2 **Introduction**

3

4 The pandemic of coronavirus disease 2019 (COVID-19) caused by a new zoonotic
5 coronary virus, SARS CoV2, has affected over 8.5 million people and caused over
6 450,000 deaths across the world as of 21 June 2020¹ having a profound impact on
7 health services and public health. The clinical spectrum of SARS-CoV-2 infection
8 appears to be wide, encompassing asymptomatic infection in a minimum of 5%, mild
9 upper respiratory tract illness with fever, fatigue, cough with or without sputum
10 production in 81%, to more severe viral pneumonia in 14% with ground-glass opacity
11 computed tomography of the chest leading to critical illness in 5% associated with
12 respiratory failure, septic shock and/ or multi-organ failure.² Case-fatality rate ranges
13 from 0.4% to 2.9% on average between different regions.²

14 Large descriptive studies have reported type 2 diabetes in 7.4% - 9.6% of patients
15 with COVID-19 and hypertension in 15% as two of the most prevalent co-morbid
16 conditions.^{3,4,5} Moreover, diabetes (16.2%) and hypertension (23.7%) are highly
17 prevalent among those with severe manifestations.³ Of patients admitted to intensive
18 care unit, 22% of those who died had diabetes.⁶

19 SARS CoV2 virus binds angiotensin-converting enzyme 2 (ACE2);^{7,8} in humans,
20 ACE2 is expressed broadly including epithelial cells of the lung, intestine, kidney,
21 heart and blood vessels.⁹ The virus downregulates the ACE2 protein expression in a
22 replication dependent manner¹⁰ resulting in loss of ACE2 function. Whether variation
23 in ACE2 expression contributes to the virulence in the current pandemic of COVID-19
24 is still unclear. There is an ongoing debate as to whether and how the interaction
25 between the virus, hypertension and ACE2 may influence the manifestations of
26 COVID-19.^{11,12,13} Concerns have been raised that angiotensin converting enzyme

1 inhibitors (ACEIs), angiotensin II type 1 receptor blockers (ARBs) and
2 thiozolidinediones often prescribed in patients with diabetes, hypertension and
3 cardiac disease may increase the risk of COVID-19 and its clinical outcomes.^{11,12,14} In
4 contrast, ACE2 is a counter regulatory enzyme that degrades angiotensin II, hence,
5 reducing its effect on vasoconstriction, sodium retention and fibrosis. Therefore, trials
6 of losartan as a treatment for Covid-19 are underway enrolling patients who have not
7 previously received treatment with ACEIs or ARBs.¹⁵ In addition, dipeptidyl
8 peptidase-4 (DPP4), the receptor for Middle East respiratory syndrome-related
9 coronavirus (MERS-CoV) has been shown to have similar expression profile to ACE2
10 in the lung.¹⁶ DPP4 inhibitors are commonly used in the treatment of type 2 diabetes.
11 We have investigated whether any of the medications for chronic conditions, in
12 particular antihypertensive and antidiabetic medications affected either the
13 development and/ or severity of COVID-19 using a multi-center cohort of 578 patients
14 with common, severe or critical form of COVID-19 and 48,667 population-based
15 control subjects from Zhejiang province, China.

16

17 **Patients and Methods**

18 The study protocol conformed to the ethical guidelines of the 1975 Declaration of
19 Helsinki. The local ethics committees of all hospitals approved the retrospective
20 study of cohorts COVID-19. The requirement for written consent was waived due to
21 the retrospective and anonymous nature of this study.

22 *Cohort of Cases*

23 Consecutive patients presenting to 14 hospitals in Zhejiang province, China (see
24 collaborators) between Jan 10 and Feb 28, 2020 and confirmed diagnosis of COVID-

1 19 infection were included (**Figure 1**). The diagnosis of COVID-19 was made in
2 accordance with the Guidelines for the Diagnosis and Treatment of New Coronavirus
3 Pneumonia (fifth edition) formulated by the National Health Commission of the
4 People's Republic of China.¹⁷ confirmed case of COVID-19 was defined as a positive
5 result on real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay
6 of nasal and pharyngeal swab specimens. Only laboratory-confirmed cases were
7 included in the study. The clinical data of all patients were collected from the
8 electronic medical records. All patients were administered with antiviral and
9 supportive treatment, and prevention of complications based on their clinical
10 condition.

11 *Clinical categories*

12 The severity of the disease was classified into 4 categories according to the
13 Guidelines for the Diagnosis and Treatment of New Coronavirus Pneumonia (fifth
14 edition)¹⁷ : 1) *mild type*: patients with mild clinical symptoms and no pulmonary
15 changes on CT imaging, 2) *common type*: patients with symptoms of fever and signs
16 of respiratory infection, and having pneumonia changes on CT imaging, 3) *severe*
17 *type*: patients presenting with any one item of the following: (a) respiratory distress,
18 respiratory rate $\geq 30/\text{min}$, (b) oxygen saturation of finger $\leq 93\%$ in resting condition,
19 and (c) arterial partial pressure of oxygen (PaO₂) /oxygen concentration (FiO₂) ≤ 300
20 mmHg (1 mmHg = 0.133 kPa) or 4) *critical type*: patients meeting any one of the
21 following criteria: (a) respiratory failure requiring mechanical ventilation, (b) shock
22 and (c) requiring ICU admission requirement due to multiple organ failure. Since only
23 32 mild cases were available and they would normally not be hospitalized, these
24 were removed from the analysis (Figure 1).

25 *Population-based Control group*

1 Detailed methods and data sources used to establish an EHR-based general
2 population-based cohort study in an eastern coastal area of China has been
3 described previously.¹⁸ The control group used in the current study is from the
4 general population from Gulin town, an area of Ningbo City, Zhejiang province, China
5 which covers the catchment area one of the hospitals from which one quarter of the
6 COVID-19 patients for this study were recruited. Since 2004, all citizens are offered
7 regular health screening in Gulin Health Center. Detailed medical history is recorded
8 in Electronic Medical Record System. Gulin town was selected as a centre of the
9 ‘Mega-Project for National Science and Technology Development’ under the “13th
10 Five-Year Plan of China” for liver diseases between 2017 and January 2021. We
11 included all adult citizens had detailed medical records established by 2019. A total
12 of 48,667 adults from 60984 registered population who had electronic medical
13 records were included in this study (**Figure 1**). The following data were collected: 1)
14 age, 2) sex, 3) detailed medical history including diabetes, hypertension, malignancy,
15 other severe diseases (congestive heart failure, severe neurological diseases and
16 previous organ transplantation), 4) details of prescription drugs used to treat these
17 medical conditions and 5) personal health parameters including history of alcohol
18 consumption and smoking as well as anthropometric measurements including body
19 weight, height, waist circumference, and arterial pressure as well as 6) laboratory
20 parameters including serology for hepatitis B and C (HBsAg and anti-HCV).
21 Individuals in the control cohort whose health record showed a diagnosis of COVID-
22 19 (n=3) were removed from the analysis (Figure 1).

23 Health information systems in Gulin include different administrative databases of
24 general demographic characteristics, health check information, health insurance
25 database, inpatient and outpatient electronic medical records, chronic disease

1 management (diabetes, hypertension, malignancy, myocardial Infarction) and death
2 certificates, and so on. These databases are inherently linked to each other by a
3 unique and encoded identifier for each individual. The system was originally
4 designed in 2006 to facilitate routine primary care services for local general
5 practitioners (GPs). Since 2009, this regional system has covered nearly all health-
6 related activities of residents within this region, from birth to death, including children,
7 adolescents, pregnant women, adults and elderly people. Now 98% of permanent
8 residents are covered by the national health insurance and have registered in the
9 health information system with a valid healthcare identifier.

10 All the chronic diseases diagnosed by doctors in Gulin or outside Gulin will be
11 reported to Ningbo CDC and rechecked by department of chronic disease
12 management of Gulin hospital. All the prescription medicines of chronic diseases
13 listed above are recorded and regularly verified.

14 *Use of medication:* it is the role of Dept. of Chronic Diseases within each community
15 hospital in Zhejiang province to update the prescriptions of chronic diseases such as
16 diabetes, hypertension ,cardiovascular, cerebrovascular disease and tumors
17 regularly. From these data we were able to run a database search including for this
18 study and individuals were classified as taking a given medication if they had been
19 given a prescription for a that drug at least three times. For COVID-19 patients, the
20 medication was included only if 3 or more one-month prescriptions were filled before
21 diagnosis of COVID-19, according to the patient's records.

22 *Statistical methods*

23 Categorical variables were expressed as frequency and percentages. Continuous
24 variables were expressed as mean and standard deviations. Logistic regressions

1 were carried out either unadjusted or adjusting for age, sex and BMI. $P < 0.05$ was
2 considered statistically significant.

3

4 **Results**

5 The selection of the study population is illustrated in **Figure 1**. A total of 610 COVID-
6 19 patients were enrolled after admission from various centers in the Zhejiang
7 province (**Figure 1**). A population-based cohort from the Zhejiang province consisting
8 of 48,667 adults with health records was used as controls. The descriptive
9 characteristics, comorbidities and use of medication prior to admission available in
10 both cases and controls were compared (**Table 1**). We found that, prevalence of type
11 2 diabetes, higher BMI, presence of cardiovascular or cerebrovascular disease were
12 associated with (all increased in) the covid-19 patients (**Table 1**). We then adjusted
13 all factors for age, sex and BMI. In the case of antihypertensives we further adjusted
14 for hypertension, in the case of medication used to treat diabetes we adjusted for
15 presence of T2D.

16 All the disease conditions associated with COVID-19 remain statistically significantly
17 associated after adjustment for age, sex and BMI. There was no significant difference
18 in the use of glucocorticoids between COVID-19 and the population-based controls
19 and a significantly higher use of statins among COVID-19.

20 We found that among individuals with a diagnosis of hypertension there was no
21 difference in the use of ACEIs or beta-blockers, but individuals with COVID-19 were
22 significantly more likely to be on calcium channel blockers (CCBs) and less likely to
23 be on diuretics and on ARBs.

24 We also found that after adjustment for demographics and presence of T2D the use
25 of antidiabetic medications was significantly different in T2D patients with COVID-19

1 than in those without and this is particularly striking for use of glycosidase inhibitors
2 which are significantly less prevalent among T2D individuals infected with COVID-19,
3 and insulin and DPP-4 inhibitors which are much more likely to be used by T2D
4 people with COVID-19. (**Table 1**)

5 We compared these figures graphically between controls and different severity
6 categories in **Figure 2**. We see that although hypertension in itself is not more
7 prevalent in COVID-19 diagnosed individuals than controls, it is much more prevalent
8 in severe and critical cases (**Table 2, Figure 2A**). Type 2 diabetes, male sex, and
9 age over 65 all show a similar pattern in terms of increase prevalence with severity.
10 (**Table 2, Figure 2A**)

11 With regards to antidiabetic medications after adjusting for age, sex, BMI and
12 diabetes, glucosidase inhibitors are less prevalent among T2D affected individuals
13 symptomatic for COVID-19 and DPP-inhibitors and insulin are much more prevalent
14 among COVID-19 patients. We compared these values to those in COVID-19
15 severity categories (**Figure 2B** and **Table 3**) and we find that there is no significant
16 association between use of DPP-inhibitors and COVID-19 severity after adjustment
17 for age, sex and BMI, resulting in OR=0.32 (95%CI 0.02 -2.18; P=0.31). For insulin,
18 we observed a trend for higher use among the severe cases with OR=2.63 (95%CI
19 0.80-9.07 P=0.11) which however did not achieve statistical significance (**Table 3**).

20 We carried out a similar analysis with antihypertensive medications. We found that
21 comparing population-based controls to COVID-19 diagnosed individuals that use of
22 ARBs and diuretics was significantly less prevalent in COVID-19 cases with
23 hypertension than among hypertensive controls, whilst use of CCBs was significantly
24 more prevalent among COVID-19 cases than controls after adjustment for age, sex
25 and BMI (**Table 1**). No significant difference in susceptibility or severity was seen

1 with use of ACEIs. (**Figure 2C, Table 3**). In terms of severity, there was a trend for
2 use of beta-blockers to be more prevalent in severe and critical cases than in mild
3 and common cases. However, after adjustment for age, sex and BMI none of the
4 antihypertensive medications was significantly associated with COVID-19 severity.
5 (**Figure 2C, Table 3**)

6 The only type of medications which remained associated with COVID-19 severity
7 after adjustment for age, sex and BMI were immunosuppressive drugs
8 (glucocorticoids) with an OR =5.37 (95%CI 0.88-41.15; **Table 3**)

9

10 **Discussion**

11 Recent descriptive cohort studies have reported type 2 diabetes in 7.4% - 9.6% of
12 patients with COVID-19 and hypertension in 15% as two of the most prevalent
13 chronic health conditions.^{3-5,19} Using a case-control design involving 610 patients
14 with COVID-19 and a well- characterized 48,667 population-based controls from the
15 South-east region of China, we have identified higher BMI, diabetes and cardio/
16 cerebrovascular disease as independent risk factors for the development of COVID-
17 19. We found the prevalence of hypertension to be slightly higher among patients
18 (22.4%), but this was not statistically significant compared to its prevalence of 20.2%
19 in the population-based control group. Furthermore, age (>65 years), sex (male) and
20 BMI were associated with the development of severe disease in 128 out of 610 of
21 those with COVID-19. In addition, when adjusted for age, sex and BMI, those with
22 history of hypertension have over two-fold risk of developing severe form of COVID-
23 19.

1 The analysis of medications acting on renin-angiotensin-aldosterone system
2 demonstrates that patients with COVID-19 were significantly less likely compared to
3 population-based controls to be taking ARBs (8.7% vs 15.4%) and diuretics in (2.1%
4 vs 5.1%) prior to their presentation, after adjusting for covariates such as age, sex
5 and BMI) as well as presence of hypertension. In contrast, CCBs were associated
6 with increased risk of COVID-19. Although hypertension is clearly a risk factor for
7 severity, we found that none of the anti-hypertensive medications were positively
8 associated with severity of the disease. In the case-control analysis, patients with
9 type 2 diabetes, treatment with dipeptidyl peptidase-4 inhibitors and insulin were
10 associated with increased risk of COVID-19 while glucosidase inhibitor therapy was
11 associated with reduced risk. It has been suggested that DPP4 residues might
12 interact with SARS-CoV-2 S1 domain of the Spike protein, also targeted by other
13 coronaviruses that enter the host cells through the functional receptor DPP4.²⁰ In
14 addition to its catalytic functions DPP4 also has a role in immune mechanisms and
15 inflammatory process²⁰ which may be influenced by DPP4 inhibitors. Treatment with
16 insulin may also reflect the degree of insulin resistance, a well-established risk factor
17 for COVID-19. Alpha glucosidase inhibitors improve glycemic control by acting on
18 intestinal membrane-bound enzymes; their effect on the cellular entry of SARS CoV-
19 2²¹ is unclear. In contrast to their association with the development of COVID-19,
20 none of the antidiabetic drugs were associated with the severe or critical form of the
21 disease. To our knowledge, these associations of antidiabetic medications with
22 COVID-19 infection haven't been demonstrated so far. The higher intake of anti-
23 diabetic medications might be linked to a longer duration or lower glycaemic control
24 and points to the role of metabolic inflammation in predisposing individuals to
25 developing the more severe form of the disease.²²

1 Among medications, corticosteroids intake at baseline were the only group that
2 increased the risk of severity of COVID-19, but this affected only 2.1% of patients. In
3 the study from OpenSAFELY collaborative, patients with asthma with recent oral
4 steroid treatment had 25% additional risk of in-hospital mortality.²³ Although in the
5 latter study, oral steroid treatment was used as a marker of severity, the effect on the
6 disease outcome could be related to recent exposure to corticosteroid.

7 The concerns raised regarding the safety of ACEIs and ARBs in relation to COVID-
8 19, are based on the hypothesis that medications acting on renin-angiotensin-
9 aldosterone system may raise the expression of ACE2, postulated receptor for
10 SARS-CoV-2.^{14,24-26} The virus uses human ACE2²⁷ expressed in lung alveolar
11 epithelial cells to trigger the key manifestations and complications of the infection.
12 ACE2 is involved in the hydrolysis of angiotensin I and II into inactive forms 1–9 and
13 1–7 respectively.¹⁵ Angiotensin 1–7 act on the Mas receptor to play a protective role
14 through vasodilatory and anti-inflammatory properties, hence, balancing the actions
15 of angiotensin II on the type 1 receptor.^{14,15} Concerns regarding both ACEI and ARBs
16 have led to calls for discontinuation of these drugs both prophylactically and in those
17 with suspected COVID-19.¹⁵ In contrast, using a large longitudinal population-based
18 control group and a multi-centre cohort of COVID-19 cases, we have demonstrated
19 that those on ARBs are significantly less likely (OR: 0.22 [95% CI 0.15-0.30]) to
20 develop COVID-19. Potential benefit from ARBs in this context may be related to the
21 effect of SARS-CoV-2 which once gaining entry through ACE2 into type II
22 pneumocyte downregulates ACE2 leading to unabated angiotensin II induced organ
23 injury. In a mouse model, SARS-CoV-1 induced lung injury could be limited by renin-
24 angiotensin-aldosterone system blockade.²⁸ Our analysis hasn't shown ACEIs to
25 have an effect similar to ARBs, consistent with the observations that ACEIs currently

1 in clinical use do not directly affect ACE2 activity.²⁹ We are not aware of any
2 population based case-control studies thus far investigating risk factors increasing
3 susceptibility to COVID-19, however, a systematic review³⁰ found that ACEIs reduced
4 the risk of pneumonia. In the latter study, the benefits of ACEI were substantially
5 greater among Asian patients and these were attributed to a higher prevalence of
6 ACE polymorphisms increasing the ACEI levels and kinin catabolism in this ethnic
7 group.

8 Of 578 with COVID-19, 128 developed severe or critical form of the disease, higher
9 proportion of patients (42.8%) with common form of the disease were on ARBs
10 compared to severe/critical (35.1%) form of the disease. However, neither ARBs nor
11 ACEI were significantly associated with the severity of COVID-19. A cohort study
12 from Wuhan province, demonstrated lower (3.7%) 28-day all-cause mortality among
13 188 patients with COVID-19 receiving ARBs or ACEI in-hospital compared 9.8%
14 among those who weren't receiving these drugs.³¹ That study was not powered to
15 evaluate the effect of ACEIs vs ARBs. In addition, lower proportion of patients with
16 COVID-19 overall were on ARBs or ACEIs than expected^{32,33} raising the possibility
17 that concerns regarding these drugs at the beginning of the epidemic may have
18 resulted in change in medication in patients on admission, In-hospital use of ACEI
19 has previously been shown to be associated with lower rate of ventilation and in-
20 hospital mortality with viral pneumonias.³⁴

21 Our case-control analysis showed that those taking CCBs had significantly increased
22 risk [OR 1.73 (95% CI 1.2-2.3)] of manifesting symptoms of COVID-19. Two recent

1 studies have shown consistent findings regarding the association between CCBs and
2 increased risk of COVID-19 associated symptoms.^{35, 36} The mechanisms underlying
3 these findings are unclear as there is no evidence that either CCBs altering ACE2
4 expression. One study including 4792 hospitalised pneumonia (bacterial and viral)
5 case, showed increased incidence of major cardiovascular events among those who
6 were on CCBs, betablockers or corticosteroids.³⁷ Impaired induction of anti-viral type
7 1 interferon response to a range of respiratory viruses has been well described in
8 association with corticosteroids and may also apply in the context of COVID-19
9 explaining association of these drugs with the severity of infection in our cohort.^{38,39}

10 Hypertension was a strong risk factor for the development of the severe and critical
11 forms of COVID-19 independently of antihypertensive therapy. This may be related to
12 higher levels of endothelin in hypertensive patients and its effect on innate immune
13 response. There is strong evidence that the innate immune response is key in the
14 development of severe COVID-19.⁴⁰ Recent data suggest that macrophages
15 contribute to, and protect from, hypertension and that macrophage depletion
16 augments the chronic hypertensive response to endothelin-1, (ET-1).⁴¹ High levels
17 ET-1 are linked to lung damage in HIV infection.⁴² It is thus possible that arterial
18 hypertension which is linked to higher levels of ET-1, more vasoconstriction, and
19 lower blood flow, may be contributing to lower levels of macrophages (i.e. lower
20 innate immune response) and potentially to build-up of fluid in the lungs (pulmonary
21 oedema).

22 Our study has a number of strengths. The case-control design with cases from
23 multiple hospitals and a large, prospective, population-based control group with 98%
24 coverage of the local population has provided the power needed to identify
25 independent risk factors including medication use to assess the risk factors for

1 COVID-19 in this population. We have included consecutive cases from each of the
2 secondary care hospitals to reflect the full range of case-mix seen in routine clinical
3 practice. Case definition and assessment of severity of COVID-19 were adherent to
4 national guidelines consistently across all the centers involved in this study.¹⁶

5 The limitations of our study include the retrospective nature of the COVID-19 cohort,
6 which could lead to possible under-recording of some less common comorbidities
7 and drug history, in particular related to use of glucocorticoids. Even though we
8 included 578 cases, we may have modest power to evaluate potential risk factors
9 with low frequency. In the large case series (n=1099) of COVID-19 patients,³ a
10 number of co-morbidities such as cardiovascular (2.5%), cerebrovascular (1.4%) and
11 chronic obstructive pulmonary diseases (1.1%) were infrequent and cancers,
12 immunodeficiency and chronic kidney disease altogether formed 1.8% of the COVID-
13 19 cases. Most patients with cardiovascular comorbidities qualify for
14 angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker
15 (ARB) therapy. However, prescribing patterns of these drugs vary widely from China
16 to the UK where ACEIs are much more commonly prescribed.⁴³ Although with a
17 much larger sample size this may prove to be significant if the effect is real, this
18 compared poorly with other factors contributing to severity such hypertension (OR
19 2.8) or the use of immunosuppressants (OR 5.37). In addition, low case-fatality rate
20 of 0.6% means that we were not able to assess risk factors associated with mortality.
21 Another limitation is the lack of pre-pandemic data on glycemic control, since DPP4
22 inhibitors and insulin are usually prescribed to patients with poorer glycemic control
23 than those receiving glucosidase inhibitors. Therefore, differences in severity seen
24 between these medication categories could be reflecting differences in glycemic
25 control and not necessarily an effect of the medication on disease progression.

1 Moreover, although all the medications included corresponded to prescriptions filled
2 3 or more times before diagnosis of COVID-19 we were unable to adjust for length of
3 use of the medications and the current analysis did not adjust for multiple testing so
4 some of the more modest associations are viewed with caution. Finally, some of the
5 associations show strong statistical significance but, as is the case for CCBs, the
6 odds ratios are < 2.0 and therefore they may not be of high clinical impact.

7 **Conclusion / Clinical relevance**

8 We have identified higher BMI, diabetes and cardio/ cerebrovascular disease as
9 independent risk factors for the development of COVID-19. Prior treatment with ARBs
10 and diuretics was associated with reduced risk and CCBs with increased risk of
11 developing COVID-19. Other antihypertensive drugs were not associated with
12 increased risk of severe or critical form of the infection. So, we found no evidence to
13 alter ARBs or ACEIs therapy in the context of the pandemic. We have also found first
14 time, increased risk of COVID-19 in association with DPP4 inhibitors and insulin as
15 reduced risk with glucosidase inhibitors. If replicated, these findings have clinical and
16 potentially public health implications.

17
18

19 **Author contributions**

20 AMV, AV and GPA wrote the manuscript; HY, TC and GPA designed the research; HY,
21 SW, LL, SY, HW, XT, JD, SJ, KH, FJ, SZ, NZ, YH, TC. performed the research; AV
22 and AMV analyzed the data;

23

24 **Collaborators:**

- 1 1. Department of Infectious Diseases, Hwamei Hospital, Ningbo No.2 Hospital,
2 University of Chinese Academy of Sciences., Ningbo 315010, China;
- 3 2. NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital
4 of Wenzhou Medical University, Wenzhou 325000, China;
- 5 3. Department of Critical Care Medicine, Wenzhou Central Hospital, Wenzhou
6 325000, China;
- 7 4. Department of Infectious Diseases, Ruian People's Hospital, Wenzhou 325200,
8 China;
- 9 5. Department of Infectious Diseases, Shaoxing people's Hospital, Shaoxing
10 312000, China;
- 11 6. Department of Infectious Diseases, Zhoushan Hospital, Zhoushan 316004, China;
- 12 7. Department of Infectious Diseases, Jiaxing First Hospital, 314000 Jiaxing, China;
- 13 8. Department of Infectious Diseases, Wenling First people's Hospital, Taizhou
14 317500, China;
- 15 9. Department of Infectious Diseases, Hangzhou Xixi Hospital, Hangzhou 310023,
16 China;
- 17 10. Department of Infectious Diseases, Taizhou Enze Medical Center (Group) Enze
18 hospital, Taizhou 317000, China;
- 19 11. Department of Infectious Diseases, The First people's Hospital of Yuhang District,
20 Hangzhou 310006, China;
- 21 12. Department of Infectious Diseases, Ningbo Yinzhou people's Hospital, Ningbo
22 315040, China;
- 23 13. Department of Infectious Diseases, Huzhou Central Hospital, Huzhou 313003,
24 China;
- 25 14. Department of Infectious Diseases, Shulan (hangzhou) Hospital Affiliated to

1 Zhejiang Shuren University Shulan International Medical College, Hangzhou
2 310004, China.

3

4

5 **References**

6

7 1. WHO report-90. WHO, COVID-19 situation report-90.

8 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200620-covid-19-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200620-covid-19-sitrep-152.pdf?sfvrsn=83aff8ee_4)
9 [sitrep-152.pdf?sfvrsn=83aff8ee_4](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200620-covid-19-sitrep-152.pdf?sfvrsn=83aff8ee_4). Accessed 21 June 2020

10

11 2. Wu Z. Characteristics of and Important Lessons From the Coronavirus Disease
12 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the
13 Chinese Center for Disease Control and Prevention. *JAMA*. 323 (13), 1239-1242
14 (2020).

15

16 3. Guan WJ. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N*
17 *Engl J Med*. 382, 1708- 1720 (2020).

18

19 4. Shi Q. et al. Diabetic Patients with COVID-19, Characteristics and Outcome: A
20 Two-Centre, Retrospective, Case Control Study. (2020); Available at
21 <http://dx.doi.org/10.2139/ssrn.3551369> (preprint)

22

23 5. Huang C. et al. Clinical features of patients infected with 2019 novel coronavirus in
24 Wuhan, China. *Lancet*. 395, 497–506 (2020).

25

26 6. Yang X. et al. Clinical course and outcomes of critically ill patients with SARS-
27 CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational
28 study. *Lancet Resp Med*. 8(5), 475- 481 (2020).

29

30 7. Li W. et al. Receptor and viral determinants of SARS-coronavirus adaptation to
31 human ACE2. *Nature*. 24, 1634–43 (2005).

32

33 8. Hoffmann M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and
34 Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 181, 271-280.e8 (2020).

35

36 9. Hamming I. et al. Tissue distribution of ACE2 protein, the functional receptor for
37 SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol*. 203,
38 631–7 (2004).

39

40 10. Dijkman R. et al. Replication-dependent downregulation of cellular angiotensin-
41 converting enzyme 2 protein expression by human coronavirus NL63. *J Gen Virol*.
42 93, 1924–9 (2012).

43

44 11. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in
45 the COVID-19 pandemic? *J of Hypertension*. 38, 781–2 (2020).

46

- 1 12. Fang L. et al. Are patients with hypertension and diabetes mellitus at increased
2 risk for COVID-19 infection? *Lancet Resp Med.* 8(4), e21-2600(20)30116-8 (2020).
- 3 13. Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in covid-19.
4 *BMJ.* 369, m1313 (2020).
- 5 14. Li, G. et al. Antihypertensive treatment with ACEI/ARB of patients with COVID-19
6 complicated by hypertension. *Hypertens Res.* 43, 588- 590 (2020).
- 7
8 15. Vaduganathan M. et al. Renin–Angiotensin–Aldosterone System Inhibitors in
9 Patients with Covid-19. *N Engl J Med.* 382, 1653- 1659 (2020).
- 10
11 16. Filardi T, Morano S.J COVID-19: is there a link between the course of infection
12 and pharmacological agents in diabetes? *J Endocrinol Invest.* 3, 1-8 (2020).
- 13
14 17. National Health Commission of the people’s Republic of China. The Guidelines
15 for the Diagnosis and Treatment of New Coronavirus Pneumonia (fifth edition).
16 Available from: [www.nhc.gov.cn/yzygj/
17 s7653p/202002/3b09b894ac9b4204a79db5b8912d44_40.shtml](http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d44_40.shtml)
- 18
19 18. Lin H. et al. Using big data to improve cardiovascular care and outcomes in
20 China: a protocol for the Chinese Electronic health Records Research in Yinzhou
21 (CHERRY) Study. *BMJ Open.* 8, e019698 (2018).
- 22
23 19. Wang D. et al. Clinical characteristics of 138 hospitalized patients with 2019
24 novel coronavirus infected pneumonia in Wuhan, China. *JAMA.* 323(11), 1061-1069
25 (2018).
- 26
27 20. Vankadari N, Wilce JA. Emerging Wuhan (COVID-19) coronavirus: glycan shield
28 and structure prediction of spike glycoprotein and its interaction with human CD26.
29 *Emerg Microbes Infect.* 9(1), 601–604 (2020).
- 30
31 21. Zhao X. et al. Inhibition of Endoplasmic Reticulum-Resident Glucosidases
32 Impairs Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus
33 NL63 Spike Protein-Mediated Entry by Altering the Glycan Processing of Angiotensin
34 I-Converting Enzyme 2. *Antimicrobial Agents and Chemotherapy.* 59(1), 206-216
35 (2014).
- 36
37 22. Bornstein S. et al. Endocrine and metabolic link to coronavirus infection. *Nature*
38 *Rev Edocrinology.* 16, 297- 298 (2020).
- 39
40 23. Williamson E. et al. Factors associated with COVID-19-related death using
41 OpenSAFELY. *Nature.* (2020).
- 42
43 24. Bozkurt B. et al. HFSA/ACC/AHA Statement Addresses Concerns Re: Using
44 RAAS Antagonists in COVID-19. *American Heart Association Professional Heart*
45 *Daily.* March 19, (2020).
- 46

- 1 25. Phadke M, Saunik S. Rapid Response: Use of angiotensin receptor blockers
2 such as Telmisartan, Losartsan in nCoV Wuhan Corona Virus infections – Novel
3 mode of treatment. *BMJ*. 368, m406 (2020).
- 4 26. Ferrario CM. et al. Effect of Angiotensin-Converting Enzyme Inhibition and
5 Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2.
6 *Circulation*. 111, 2605-2610 (2005).
- 7 27. Lu R. et al. Genomic characterisation and epidemiology of 2019 novel
8 coronavirus: implications for virus origins and receptor binding. *Lancet*. 395(10224),
9 565-574 (2020).
- 10 28. Kuba K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS
11 coronavirus-induced lung injury. *Nat Med*. 11, 875-9 (2005).
- 12 29. Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensin-converting
13 enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide
14 metabolism. *Biochem J*. 383, 45-51 (2004).
- 15
16 30. Caldeira D. et al. Risk of pneumonia associated with use of angiotensin
17 converting enzyme inhibitors and angiotensin receptor blockers: systematic review
18 and meta-analysis. *BMJ*. 345, e4260 (2012).
- 19
20 31. Zhang P. et al. Association of Inpatient Use of Angiotensin Converting Enzyme
21 Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With
22 Hypertension Hospitalized With COVID-19. *Circulation Res*. 126, 1671-1681 (2020).
- 23
24 32. Wang Z. et al. Status of hypertension in China: results from the China
25 Hypertension Survey, 2012-2015. *Circulation*. 137, 2344-56 (2018).
- 26
27 33. Lu J. et al. Prevalence, awareness, treatment, and control of hypertension in
28 China: data from 1 · 7 million adults in a population-based screening study (China
29 PEACE Million Persons Project). *Lancet*. 390, 2549-58 (2017).
- 30
31 34. Henry C. et al. Impact of angiotensin-converting enzyme inhibitors and statins on
32 viral pneumonia. *Baylor Univ Med Cent Proc*. 31, 419–423 (2018).
- 33
34 35. Reynolds HR. et al. Renin–angiotensin–aldosterone system inhibitors and risk of
35 Covid-19. *N Engl J Med*. 382, 2441- 2448 (2020).
- 36
37 36. Mancia G. et al. Guidelines for the management of hypertension and target organ
38 damage. *J of Hypertension*. 31 (12), 2464- 2465 (2013).
- 39
40 37. Steiner GS. et al. Bacterial pneumonia compared to viral pneumonia is
41 associated with a higher risk of future major adverse cardiovascular events.
42 Presented at: American Heart Association Scientific Sessions 2018; November 10-
43 12, 2018; Chicago, IL. Available at:
44 <https://www.abstractsonline.com/pp8/#!/4682/presentation/51526>

- 1 38. Singanayagam, A. et al. Corticosteroid suppression of antiviral immunity
2 increases bacterial loads and mucus production in COPD exacerbations. *Nat*
3 *Commun.* 9, 2229 (2018).
4
- 5 39. Thomas, B. et al. Glucocorticosteroids enhance replication of respiratory viruses:
6 effect of adjuvant interferon. *Sci Rep.* 4, 7176 (2015).
7
- 8 40. Shi Y. et al. COVID-19 infection: the perspective of immune response. *Cell Death*
9 *& Diff.* 27, 1451- 1454 (2020).
10
- 11 41. Czopek A. et al. A novel role for myeloid endothelin-B receptors in hypertension.
12 *Eur Heart J.* 40(9), 768-784 (2020).
13
- 14 42. Head BM. et al. Inflammatory mediators and lung abnormalities in HIV: A
15 systematic review. *Plos One.* 14(12), e0226347 (2019).
16
- 17 43. Mahmoudpour HS. et al. Prescription patterns of angiotensin-converting enzyme
18 inhibitors for various indications: A UK population-based study. *Br J Clin Pharmacol.*
19 84(10), 2365–2372 (2018).
20
21
22
23
24
25
26
27
28
29

1 **Table 1.** Comparison between Covid-19 cases and controls, showing univariate odds ratios from logistic regression, and odds ratios
 2 adjusted for age, sex and BMI
 3

	controls	COVID-19	OR	unadjusted			adjusted for age, sex, BMI			
				95% CI	p-value	OR	95% CI	p-value		
n	48667	578								
sex M	23506	293	1.10	0.93	1.29	0.25				
n (%)	48.3%	(50.7%)								
Age years mean (SD)	49.96 (16.69)	49.18 (14.16)	1.00	0.99	1.00	0.273				
BMI kg/m ² mean (SD)	22.79 (2.86)	24.01 (3.43)	1.13	1.10	1.16	<0.0001				
Smoke	4725	53	0.90	0.66	1.19	0.477	0.71	0.51	0.98	0.071
n (%)	(9.7%)	(9.2%)								
HBV	2287	32	1.22	0.84	1.71	0.275	1.27	0.86	1.81	0.201
n (%)	(4.7%)	(5.5%)								
Diabetes	2920	57	1.70	1.28	2.22	0.0001	1.53	1.15	2.11	0.004
n (%)	(6.1%)	(9.8%)								
Hypertension	9855	130	1.18	0.97	1.43	0.084	1.01	0.76	1.31	0.851
n (%)	(20.2%)	(22.4%)								
Cardio or cerebrovascular disease	622	15	2.16	1.25	3.45	0.002	2.26	1.22	3.76	0.006
n (%)	(1.3%)	(2.6%)								
Tumour	973	10	0.86	0.43	1.53	0.648	0.92	0.51	1.73	0.991
n (%)	(2.0%)	(1.8%)								
Glucocorticoids	326	5	1.29	0.46	2.82	0.568	1.17	0.41	2.73	0.717
n (%)	(0.6%)	(0.8%)								
ACEI	555	5	0.75	0.27	1.64	0.538	0.61 ⁽¹⁾	0.23	1.51	0.362
n (%)	(1.1%)	(0.8%)								
ARB	7485	50	0.56	0.41	0.73	<0.0001	0.22 ⁽¹⁾	0.15	0.30	<0.0001
n (%)	(15.4%)	(8.7%)								
CCB	4740	84	1.61	1.27	2.01	<0.0001	1.73 ⁽¹⁾	1.21	2.31	0.001
n (%)	(9.7%)	(14.6%)								
Diuretic	2467	12.31	0.43	0.24	0.72	0.003	0.30 ⁽¹⁾	0.19	0.58	<0.0001
n (%)	(5.1%)	(2.1%)								
Beta.blockers	1221.54	15	0.96	0.53	1.57	0.892	0.80 ⁽¹⁾	0.42	1.47	0.468
n (%)	(2.5%)	(2.3%)								
Glycosidase inhibitors	2019	15	0.66	0.38	1.05	0.104	0.11 ⁽²⁾	0.10	0.41	<0.0001
n (%)	(4.1%)	(2.6%)								
Biguanides	1445	28	1.64	1.09	2.37	0.010	1.00 ⁽²⁾	0.58	1.62	0.975

n (%)	(2.9%)	(4.9%)								
Insulin secretagogues	700	16	1.92	1.12	3.06	0.010	1.23 ⁽²⁾	0.72	2.29	0.395
n (%)	(1.4%)	(2.8%)								
Thiazolidinediones	394	3	0.64	0.16	1.68	0.446	0.36 ⁽²⁾	0.11	1.21	0.121
n (%)	(0.8%)	(0.5%)								
DPP-4 inhibitors	486	6	9.22	3.54	19.82	<0.0001	6.02 ⁽²⁾	2.30	15.51	<0.0001
n (%)	(0.1%)	(0.9%)								
Insulin	701	16	3.29	1.86	5.34	<0.0001	2.71 ⁽²⁾	1.57	5.51	0.0002
n (%)	(1.4%)	(2.8%)								
Statins	443	15	2.82	1.60	4.57	<0.0001	2.50	1.48	4.21	0.001
n (%)	(0.9%)	(2.6%)								
Fibrates	63	0	0.05	0.00	30.12	0.417	0.03	0.00	29.26	0.339
n (%)	(0.1%)	(0.0%)								
Aspirin	673	10	1.45	0.75	2.53	0.220	1.28	0.57	2.63	0.512
n (%)	(1.3%)	(1.8%)								

(1) in n=134 covid-19 patients with hypertension

(2) in n=58 covid-19 patients with Type 2 Diabetes

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

1 **Table 2.** Association between demographics, clinical presentation at admission, comorbidities and use of medication and COVID-19
 2 severity. odds ratios were derived by logistic regression severe (severe+ critical) vs not severe (common). p-values adjusted for
 3 age, sex and BMI, except those for age, sex and BMI

Severity category	2 (common)	3+4 (severe + critical)	adj OR severe vs not	95% CI	p-value	
n	450	128				
sex M (n, %)	207, 46%	86, 67%	2.40	1.59	3.65	P<0.0001
Age years mean (SD)	47.26 (13.53)	56 (14.29)	1.04	1.03	1.06	P<0.0001
BMI kg/m2 mean (SD)	23.63 (3.29)	25.38 (3.59)	1.15	1.09	1.23	P<0.0001
Clinical presentation						
Fever n (%)	365.5 (81.3%)	109.9 (85.9%)	1.61	0.42	2.50	0.111
Cough n (%)	296.64 (65.9%)	102.98 (80.4%)	2.13	1.33	3.49	0.002
digestive symptoms n (%)	52.02 (11.5%)	20 (15.6%)	1.42	0.80	2.44	0.220
systolic BP mmHg mean (SD)	131.65 (19.29)	133 (18.17)	0.97	0.95	1.30	0.011
diastolic BP mmHg mean (SD)	81.07 (10.85)	78.75 (10.08)	0.96	0.93	0.99	0.009
respiratory rate mean (SD)	19.42 (1.80)	20.86 (4.58)	1.22	1.08	1.33	0.002
peak temperature C mean (SD)	37.88 (0.77)	38.08 (0.85)	1.38	1.06	1.80	0.018
days since disease onset mean (SD)	6.15 (5.15)	6.57 (3.99)	1.01	0.97	1.01	0.637
hospital length of stay mean (SD)	19.31 (18.63)	21.18 (9.87)	1.00	1.00	1.01	0.363
Death n (%)	0 0.00%	16.5 12.90%	1054.07	0.00	inf	0.350

Comorbidities						
Smoke	31	20	0.88	0.45	1.74	0.728
n (%)	(6.9%)	(15.6%)				
Chronic Liver Disease	27	6	0.77	0.28	1.80	0.573
n (%)	(6.0%)	(4.6%)				
Diabetes	37	21	1.13	0.64	1.41	0.570
n (%)	8.2%	15.6%				
Hypertension	77	57	2.88	1.54	4.96	0.0007
n (%)	(17.1%)	(44.5%)				
CVD cerebrovascular	10	6	1.12	0.37	3.39	0.841
n (%)	2.2%	4.6%				
Cancer	6	4	1.38	0.42	7.18	0.284
n (%)	1.3%	3.1%				

1
2
3
4
5

1 **Table 3.** Association between the use of medication and COVID-19 severity. odds ratios were derived by logistic regression severe
 2 (severe+ critical) vs not severe (common). p-values adjusted for age, sex and BMI

3

Severity category	2 (common)	3+4 (severe + critical)	adj OR severe vs not		95% CI	p-value
<i>use of medication</i>						
Glucocorticoids	2/450 0.4%	30/128 2.3%	5.37	0.88	41.15	0.034
ACEI (1)	2/77 2.6%	3/57 5.2%	2.08	0.33	16.22	0.855
ARB (1)	33/77 42.8%	20/57 35.1%	0.72	0.35	1.45	0.381
CCB (1)	53/77 68.8%	33/57 57.8%	0.62	0.30	1.27	0.139
Diuretic (1)	8/77 10.3%	5/57 8.7%	0.82	0.24	2.63	0.644
Beta-blockers (1)	5/77 6.4%	9/57 15.7%	2.70	0.87	9.24	0.539
Glycosidase inhibitors (2)	9/37 24.3%	7/21 33.3%	1.65	0.52	5.43	0.498
Biguanides (2)	18/37 48.6%	8/21 38.0%	0.98	0.35	2.60	0.536
Insulin secretagogues (2)	10/37 27.0%	5/21 23.8%	0.84	0.23	2.83	0.788
Thiazolidinediones (2)	1/37 2.7%	2/21 9.5%	3.79	0.34	84.60	0.290
DPP.4 inhibitor (2)	5/37 13.5%	1/21 4.7%	0.32	0.02	2.18	0.314
Insulin (2)	7/37 18.9%	8/21 38.0%	2.63	0.80	9.07	0.114
Statins	10/450 2.2%	5/128 3.9%	1.78	0.54	5.13	0.296
Fibrates	0.00%	NA	NA			
Aspirin	8/450 1.7%	3/128 2.3%	1.32	0.28	4.66	0.680

- 1 (1) in n=134 covid-19 patients with hypertension
- 2 (2) in n=58 covid-19 patients with Type 2 Diabetes






Figure 1: Flow chart of recruitment paths for research study participants

1
2


A



B



C



1
2 **Figure 2. (A)** Comparison of demographic and co-morbidity distribution between COVID-19 positive individuals grouped according
3 to severity compared to the control cohort. **(B)** Comparison of use of type 2 diabetes (T2D) prescribed medications across the
4 COVID-19 severity range compared to the control cohort. Error bars represent 95% CI. **(C)** Comparison of use of anti hypertensive
5 (HTN) prescribed medications across the COVID-19 severity range compared to the control cohort. Error bars represent 95% CI.

